Physician profile
Jay A Kavet
NPI 1649216581
$3,021.89
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $976.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.22 | 2019-2020 | |
| Lilly USA, LLC | $474.10 | 2019-2020 | |
| Optinose US, INC. | $354.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $245.21 | 2019-2020 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Mylan Specialty L.P. | $125.00 | 2020 | |
| Insmed, INC. | $120.97 | 2019 | |
| Mallinckrodt Hospital Products INC. | $119.39 | 2020 | |
| Glaxosmithkline, LLC. | $113.31 | 2019 | |
| Merck Sharp & Dohme LLC | $107.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Kavet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.